Summary & Overview
HCPCS Level II Q4416: Alexiguard tl-t, Topical per Square Centimeter
HCPCS Level II code Q4416 designates Alexiguard tl-t billed per square centimeter as an add-on item to be reported in addition to a primary procedure. This code captures surface-area–based application of a topical therapeutic product used during or immediately adjacent to a primary procedure. Nationally, add-on HCPCS codes like Q4416 matter because they ensure separate reporting and tracking of adjunctive materials and therapies that can affect episode costs, clinical documentation, and payer adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context and service settings, plus a summary of what to expect from payer coverage and claim processing for add-on topical products. The publication outlines benchmarking considerations, documentation expectations, and common billing practice themes relevant to facilities and clinicians that apply surface-area–based topical treatments. It also flags areas where input was not provided and where organizations typically need to confirm payer-specific rules and payment policies.
Billing Code Overview
HCPCS Level II code Q4416 describes Alexiguard tl-t, per square centimeter and is designated as an add-on, list separately in addition to primary procedure. The code represents a topical or local treatment product measured and billed by surface area (per square centimeter).
Service Type: Topical therapeutic product applied per square centimeter
Typical Site of Service: Outpatient clinic or procedural setting where topical/dermal products are applied in addition to a primary procedure
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting with a localized soft-tissue wound or dermatologic lesion in which topical tumor-treating or anti-neoplastic gel therapy is indicated as an adjunct to a primary procedure. The clinical workflow begins with diagnosis and evaluation in an outpatient dermatology or surgical clinic. The provider documents lesion size and location, obtains informed consent, and performs the primary procedure (for example, lesion debridement, excision, curettage, or biopsy). After the primary procedure, the clinician measures the treated surface area in square centimeters and applies the topical agent Q4416 as an add-on therapy to the treated field. The treated site is dressed per standard post-procedure wound care. Follow-up visits occur to assess local response, wound healing, and any adverse effects from the topical therapy. Typical sites of service include outpatient hospital departments, ambulatory surgical centers, and physician office-based procedure suites staffed by dermatology, surgical oncology, or wound care teams.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when the clinician provides an E/M service above and beyond the usual pre/post-procedure work on the day Q4416 is applied |